Full-Time
Business Development Associate
Confirmed live in the last 24 hours
Asimov
51-200 employees
Synthetic biology solutions for biopharmaceuticals
Mid
Remote in USA
Position is fully remote but focuses on the West Coast.
- At least 3 years of experience in a business development or sales role, specifically within the B2B biopharmaceutical tools sector
- A deep understanding of the therapeutics biomanufacturing landscape
- A robust and expanding network within the biopharma services and tools market
- Proven track record of managing long-term relationships with clients
- Knowledge of cell line development and upstream process development for biologics and/or viral vectors
- Actively source and secure business opportunities with biopharma companies of varying sizes
- Nurture and maintain relationships with clients throughout the entire partnership lifecycle
- Effectively convey the technical and commercial benefits of our offerings to potential clients
- Work closely with the broader commercial team to develop deal structures that maximize value
- Represent the company at industry conferences to network and promote services
- An MBA or Master's degree is preferred
- Alternatively, a Bachelor's degree in Life Sciences coupled with relevant experience will be considered
Asimov operates in the synthetic biology field, providing a combination of engineered cells, genes, and software to assist in advanced genetic design. Their main products include cloud-based software that helps clients in the biopharmaceutical industry design, simulate, and optimize genetic systems, along with engineered GMP host cells for therapeutic uses. Asimov distinguishes itself from competitors by offering a unique guarantee on their high titer cell lines for monoclonal antibodies, promising '4 g/L or it's free,' which reduces risk for their clients. The company's goal is to enable biopharma companies to enhance their production of protein therapeutics and scalable viral vectors, ensuring high quality and performance through their in-house expertise in synthetic biology and process development.
Company Stage
Series B
Total Funding
$199.1M
Headquarters
Boston, Massachusetts
Founded
2017
6 month growth
↑ 9%1 year growth
↑ 10%2 year growth
↑ 12%
Simplify's Take
What believers are saying
- Stable cell line development reduces costs and increases scalability in lentiviral production.
- Acquisition of The Foundry enhances Asimov's expertise in genetic design and engineering.
- Growing biotech investments indicate a robust market for Asimov's engineered cell lines.
What critics are saying
- Competition from LatchBio's code-free biocomputing infrastructure challenges Asimov's software offerings.
- Integration of The Foundry may lead to potential cultural clashes and operational disruptions.
- Rapid data generation in synthetic biology may strain Asimov's data processing capabilities.
What makes Asimov unique
- Asimov offers a '4 g/L or it's free' promise for monoclonal antibodies.
- The LV Edge Producer System eliminates GMP plasmid costs and reduces process complexity.
- Asimov integrates synthetic biology, computer-aided design, and machine learning for genetic design.
Help us improve and share your feedback! Did you find this helpful?